- The ENMC Consortium on congenital muscular dystrophy (CMD) held its 10th meeting in Naarden during the weekend of the 8th–10th February 2008. It was attended by 22 participants from 11 countries, including Australia, Canada, Denmark, France, Germany, Japan, Italy, The Netherlands, Turkey, United Kingdom and USA. The participants were basic scientists with a biochemical and molecular biology background, and clinicians and muscle pathologists, all sharing a substantial expertise in neuromuscular disorders.
Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, FranceTREAT-NMD (Translational Research in Europe for the Assessment and Treatment of Neuromuscular Disease) is a European neuromuscular network aimed at strengthening European excellence in the treatment of rare inherited neuromuscular disorders (NMD) by reducing fragmentation and establishing a common road map for the progression of cutting edge therapies from laboratory to clinic. Defining and disseminating information on relevant outcome measures is the object of one of the work packages of TREAT-NMD (WP 9).
- This one-day workshop was organized by Thomas Voit and assembled 13 researchers from five countries (Belgium, The Netherlands, France, Italy, USA) in order to create a collaborative interface between several international groups who are actively investigating the molecular background of facioscapulohumeral muscular dystrophy (FSHD) as well as to give an update on therapeutic projects on FSHD at the preclinical and clinical level.
- The ENMC Consortium on Congenital muscular dystrophy (CMD) held its ninth meeting in Naarden during the weekend of the 21st–23rd January 2005. It was attended by 23 participants from nine countries, including France, Germany, Japan, Italy, The Netherlands, Spain, Turkey, UK and USA. The participants were scientists from a biochemical or cell and molecular biology background, together with clinicians and muscle pathologists. A full list of participants can be found at the end of the article.
- The 134th ENMC workshop on outcome measures and treatment of SMA attended the meeting in Naarden, The Netherlands, during the weekend of the 11–13th February 2005. It was attended by 30 active participants from Belgium, France, Germany, Italy, Poland, Spain, Switzerland, Turkey, The Netherlands, United Kingdom and USA, including three patient representatives.